Company / Gross Margin
Niagen Bioscience, Inc. Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
64.3%
FY2025
5-year range
59.4% / 64.3%
FY2021-FY2025
Trend
+5.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from 59.4% to 64.3% over the past 2 years.
Based on SEC 10-K filings.
64.3% in FY2025 with a 5-year CAGR of +8.6%.
Improved from 59.4% to 64.3% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +2.8pp
- 5-Year Change
- +8.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, gross margin increased 5.8% year-over-year.
- Lowest gross margin in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 64.3% | +5.8% |
| FY2024 | 60.8% | +2.3% |
| FY2023 | 59.4% | -3.4% |
| FY2022 | 61.5% | +3.3% |
| FY2021 | 59.5% | +6.9% |
| FY2020 | 55.7% | +0.0% |
| FY2019 | 55.7% | +12.6% |
| FY2018 | 49.4% | +0.0% |
| FY2017 | 49.4% | +3.0% |
| FY2016 | 48.0% | +13.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026